Actual growth rate and tumour cell proliferation in human pulmonary neoplasms. by Kerr, K. M. & Lamb, D.
Br. J. Cancer (1984), 50, 343-349
Actual growth rate and tumour cell proliferation in human
pulmonary neoplasms
K.M. Kerr & D. Lamb
Department ofPathology, Edinburgh University Medical School, Teviot Place, Edinburgh EH8 9AG, UK.
Summary Measurement of the Doubling Times [DT] for 27 human pulmonary neoplasms have been made.
Squamous and large cell tumours had a wide range of values for DT whereas for small cell undifferentiated
carcinoma, and possibly large cell undifferentiated carcinomata without stratification, the range was narrower.
Mean DT for different primary bronchogenic carcinoma groups were: Squamous cell 146 days,
Adenocarcinoma 72 days, Small cell 66 days, and Large Cell 111 days. The number of adenocarcinomata is
very small in number and our value of 72 days is probably not representative of this group of tumours.
Relationship between DT and tumour differentiation was difficult to identify in our series.
Of these 27 a unique series of 17 have parallel data on DT and Potential Doubling Time (DTpot) and the
Cell Loss Factor [0] calculated. Great discrepancy between DT and DTpot existed in each case and cell loss
was high, ranging from 54% to 99%. All primary bronchogenic carcinomata had cell loss of >70%; in
almost two thirds of these cases the value was 90% or more. All undifferentiated tumours and a majority of
poorly differentiated tumours had cell loss of 90% or more. As cell loss increased, tumour thymidine labelling
index (TLI) increased and the tumours tended to be less well differentiated. The relationship, if any, between
cell loss and DT was unclear.
The concept of tumour growth measurement by
studying serial X-ray films is well established
(Charbit et al., 1971). The study of pulmonary
neoplasms, mostly metastatic lesions but also
primary tumours, accounts for most of this work
since clearly defined "coin" lesions in the lung
fields on a chest X-ray film lend themselves to
direct measurement more so than tumours in any
other site in the body (Chahinian & Israel, 1976).
In 1956 Collins et al. established a technique,
subsequently used by many others, for
measurement of lesion diameter from serial chest
X-ray films and determination of the time taken for
the lesions to double their volume, the Actual
Volume Doubling Time (DT).
Human tumour growth can be investigated at a
cellular level by in vitro tritiated ([3H]-methyl)
thymidine ([3H]-TdR) labelling of the tumour cell
population (Quastler & Sherman, 1959). Labelled
cells can be detected in histological sections by
autoradiography (see Cleaver, 1967) and the
percentage of cells labelling with [3H]-TdR, the
Thymidine Labelling Index (TLI), may be
determined. Steel (1967, 1968) has shown that TLI
can be used to estimate the time for doubling of a
tumour cell population. The time derived assumes
that all cells produced by mitosis remain viable
within the tumour and thus is known as the
Potential Doubling Time (DTpot).
Current data available on tumour growth and
cell kinetics show a considerable discrepancy
regularly exists between DT and DTpot (Malaise et
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al., 1973). The method devised by Steel for
determining DTpot from the TLI of a tumour cell
population takes account of growth fraction. It is
therefore held that "cell loss", by whichever means,
is the reason for the difference between the rate at
which a tumour cell population doubles its volume
and the rate at which the tumour cell mass actually
doubles (Steel, 1967; Steel & Lamerton, 1969). Steel
coined the term "Cell Loss Factor" (0) for
expressing this difference (see Materials and
methods).
Cell loss factor for human tumours has, due to
lack of parallel data, been estimated using results
pooled from various sources in the literature (Terz
et al., 1971; Malaise et al., 1973; see Steel, 1977). In
this paper we present a series of twenty seven
human pulmonary neoplasms for which DT has
been determined. In seventeen of these cases
parallel data on DT and DTpot have been obtained
and cell loss factors deduced.
Materials and methods
We have already reported a series of 58 human
pulmonary neoplasms on which TLIs were
determined using an in vitro technique (Kerr et al.,
1983). All 57 patients (one patient had two
metastases resected) had carcinomata removed at
thoracotomy in the Thoracic Surgical Unit, City
Hospital, Edinburgh. In 17 of these cases serial
chest X-ray films were obtainable with
"measurable" (vide infra) shadows.
Ten measurable tumours, without kinetic data,
were obtained from 46 other patients.
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Histological classification oflung tumours
The tumours were classified histologically on the
material taken from the resected specimen for
diagnostic purposes according to a modification of
the WHO classification of lung tumours previously
used by us (Kerr et al., 1983).
Of the 17 cases with parallel data and 9
estimation 14 were primary bronchogenic
carcinomata and 3 were metastatic lesions. The
former group consisted of 5 squamous carcinomata,
3 large cell undifferentiated carcinomata (2 with
and one without stratification), 3 adeno-
carcinomata, 2 small cell carcinomata and one
primary clear cell carcinoma of the lung. The latter
group comprised of 2 secondary clear cell renal
carcinomata and one deposit of undifferentiated
carcinoma (primary site unknown).
The 10 cases in the series with DT only measured
consisted of 9 primaries and one metastatic lesion.
The primary tumours were 2 squamous cell, 4 large
cell undifferentiated carcinomata (2 with and 2
without stratification), one adenocarcinoma, and 2
small cell undifferentiated bronchogenic
carcinomata. The metastatic tumour was from a
malignant melanoma.
Tumour measurement
Only standard 72 inch postero-anterior chest X-ray
films were used. A lesion was considered
measurable if >70% of the lesion's perimeter was
clearly delineated, being neither obscured by
effusions, pneumonic consolidation/collapse,
skeletal structures or mediastinal shadows, nor
undefinable due to the softness of the lesion
shadow, poor film quality or lymphangitic spread.
Measurements in millimetres were made directly
from the films viewed on a standard "light box"
using a pair of adjustable calipers. In most cases
measurement was made of the two diameters
nearest to 90° apart which could reliably be
identified from film to film. In some cases only one
diameter could be reliably measured over the series
of films. When two diameters could be measured
from the lesion on all available films of a case then
the diameter used for calculating the doubling time
was taken as the mean of the two diameters
measured. Five out of the 17 cases had only two
films measurable. The shortest period over which a
lesion was observed in this group was 0.6 of one
doubling time. Most cases were observed for more
than one doubling time. The last X-ray for each
case was within one week of operation and usually
within two days of resection of the tumours.
Assessment of tumour thymidine labelling index
(TLI)
Specimens were collected from the operating theatre
and a thin slice of tissue was taken through the
lesion including both peripheral and central areas.
This tissue was transported to the laboratory in
Eagle's MEM (Minimum Essential Medium, Gibco-
Biocult) at 4°C where it was diced into half to one
millimetre fragments using a scalpel blade.
Approximately 10 of these fragments were
incubated for 1 h at 370C in 7ml Bijou bottles
containing 5ml Eagle's MEM, with HEPES buffer,
10% heat-inactivated foetal bovine serum (HIFBS -
Flow Laboratories) and 5MCiml-' tritiated ([3H]-
methyl) thymidine (Sp. Act. 40 CimM-1 -
Radiochemical Centre, Amersham) under
hyperbaric oxygenation (Kerr et al., 1983). At 1 h
the tissue was washed and fixed in Bouin's fluid,
embedded in paraffin wax and autoradiographs
made using the dipping film technique with Ilford
K5 emulsion. Labelling indices were estimated by
counting the total nuclei and labelled nuclei (total
of between 2 and 10 x103 cells per case) in the
peripheral 75pm rim of tumour. The counting
method was devised to account for the uneven
labelling of cells (Kerr et al., 1983).
Calculating actual doubling time
This was done using a graphical method developed
by Collins et al. (1956).
Calculating potential doubling time
DTpot can be calculated by using the relationship
DTpot=ATS/TLI where A=0.75 and Ts= 15 h
(after Steel, 1967, 1968). Alternative values of
T. from the literature derived for specific cell types
of pulmonary neoplasm were also used as indicated
(Table II).
Calculating cell lossfactor (0)
Steel described this as equal to 1-DTpot/DT and
thus cell loss is described in terms of the proportion
of cells produced by mitosis which are lost from the
tumour cell population. At most 0= 1.0, i.e. all (or
100%) of the number of cells produced are lost
from the tumour, a steady state exists and thus no
growth occurs. If DT equals DTpot then the
expression for 0 equals zero (no cell loss is
occurring). As DT exceeds DTpot more and more 0
increases and tends towards 1.0 (or 100%). Thus if
0=0.9 (or 90%) then 90% of the number of cells
being produced by mitosis are being lost.
Results
Our series of cases of lung tumours on which we
had kinetic data contained 14/53 (26%) primaryGROWTH RATE AND PROLIFERATION IN LUNG CANCER 345
lesions and 3/5 (60%) metastatic tumours which
were "measurable". From the primary
bronchogenic carcinomata in the separate series
with no kinetic data 9 cases of measurable tumours
were found out of 38 examined (24%).
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Figure 1 The distribution of DT within the
histopathological groups of lung tumours. Squamous
(MD =moderately differentiated, PD =poorly
differentiated), Large Cell Undifferentiated (LCU),
with and without stratification (+S or -S). Small Cell
Undifferentiated (SCU) and Adenocarcinomata
(WD =well differentiated) are represented. The
abbreviations "I " and "2°" refer to primary and
secondary (or metastatic) tumours respectively.
The results of DT for differing histological
tumour types from both series are shown in Figure
1. Table I shows the data from this study compared
with amalgamated results from the literature on the
four major histological groups of bronchogenic
carcinoma (Schwartz, 1961; Garland et al., 1963;
Spratt et al., 1963; Spratt & Spratt, 1964; Weiss et
al., 1966; Chahinian, 1972; Israel et al., 1973;
Meyer, 1973; Steele & Buell, 1973). Several of these
authors did not make a distinction between large
cell and small cell undifferentiated carcinomata
referring to an ambiguous group of
'undifferentiated" tumours.
Data concerning tumour histological type, actual
doubling time, thymidine labelling index, potential
doubling times from assumed T, (and where
relevant, published T.) with derived cell loss factors
are shown on the seventeen cases in the parallel
study in Table II. The cases in Table II are listed in
decreasing order of % TLI and thus increasing
DTpot (assuming Ts = 15 h). The values of
published T. were as follows: Small Cell
Carcinoma, T.= 18.8h (Muggia et al., 1974), Large
Cell Undifferentiated Carcinoma, Ts= 16.5 h (Straus
& Moran, 1977), Renal (Clear Cell)
Adenocarcinoma, T.=9.2h (Rabes et al., 1979).
All the primary lung tumours show cell loss
factors of >0.7 (>70% of cells produced by
mitoses are lost). Furthermore, considering the four
categories of the common primary bronchogenic
carcinomata, 9/14 (64%) have a cell loss of .90%.
All six of the "undifferentiated" carcinomata have
cell losses of >90%; those in the "large cell"
category losing 93% or more of cells produced by
mitosis. Conversely, there is an impression that cell
loss is less in the more differentiated
adenocarcinomata of various types (primary,
primary "clear cell" and metastatic renal "clear
cell" adenocarcinoma). However, all the groups are
small and it is pertinent to comment that the largest
group (4 cases of poorly differentiated squamous
carcinoma) also shows the widest range of cell loss
of all our histopathological groups of primary lung
tumour (Figure 2).
Table I Comparison of data on DT from this series (left column) with that
in literature * (right column) oii primary bronchogenic carcinoma (see text).
Mean Meana
Histopathological DTact No. DTact No.
type days Range cases days Rangea casesa
Squamous 146 20-382 7 101 7-381 115
Adeno- 72 23-110 4 179 17-590 66
Small cell 66 24-94 4 33 17-71 5
Large cell 111 37-260 7 113 112-114 2
"Undifferentiated" 100 34-480 33
_
_
_
_
_
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Table II Compiled results on 17 pulmonary tumours on which actual and
potential growth have been studied in parallel.
Potential Actual Cell aPotential aCell
Case Histology TLI % DT(days) DT(days) loss 0 DT(days) loss 0
1 LCU 23.0 2.2 154 0.99 2.2 0.99
2 SCU 22.5 2.2 94 0.98 2.6 0.97
3 20 LCU 22.2 2.3 185 0.99
4 SCU 20.3 2.5 24 0.90 2.9 0.88
5 LCU (+S) 20.0 2.5 55 0.95 2.6 0.95
6 LCU (+S) 19.7 2.5 37 0.93 2.6 0.93
7 PDSQ 18.7 2.7 93 0.97
8 MDSQ 16.2 3.1 61 0.95 -
9 PDSQ 15.5 3.2 22 0.85 -
10 WDAD 10.3 4.9 23 0.79
11 PDAD 10.2 4.9 98 0.95
12 PDSQ 8.5 5.9 20 0.71 -
13 PDSQ 6.2 8.1 95 0.91
14 PDAD 5.6 8.9 58 0.85
15 20 Renal 3.7 13.5 92 0.85 7.7 0.92
16 1° Clear 2.9 17.2 73 0.76
17 2° Renal 0.7 71.4 155 0.54 41.1 0.73
aDTpot and 0 in these columns have been calculated using T. values from the
literature on corresponding cell types of bronchogenic carcinoma and not the
standard assumed 15h (see text).
Abbreviations used for histology are as in Figure 1 but in addition SQ
=Squamous carcinoma and AD=Adenocarcinoma.
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Figure 2 The distribution of Cell Loss (as a %)
within histopathological groups of pulmonary
tumours. Abbreviations are as before. The "y-axis"
has been shortened.
There is no apparent direct relationship between
actual doubling time of the tumour and TLI of the
tumour cell population (Table II).
The relationship between cell loss and thymidine
labelling index is shown in Figure 3. This graph
0
0
* 0
* 0
0
0
I_
0 5 10 15 20 25
T.L.I. (%)
Figure 3 The relationship between Cell Loss (%) and
% Thymidine Labelling index. The correlation
coefficient between y and x is 0.6 (P<0.0005).
suggests that, as the TLI of a tumour cell
population increases the degree of cell loss from
that tumour also increases. Thus, there appears to
be a tendency for tumours with TLI> 17% to have
cell loss factors of 90% or more whereas tumours
with TLI <5% have cell losses of <90%.
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Discussion
Obtaining actual doubling time
Between 8 and 31% of primary bronchogenic
carcinomata may be "measurable" for the purposes
of determining growthi,rate (Chahinian & Israel,
1976). Twenty-six percent of our cases on which
TLI data were available'were considered suitable
for determination of DrJ. All these cases were
surgically "operable" on clinical staging. The use of
a surgical series may have selected out cases early
in their natural history and with peripheral rather
than hilar lesions more likely to be measurable.
Calculating potential doubling time and cell loss
factor
Estimation of DTpot for a tumour cell population
from a knowledge of the thymidine labelling index
of the population is based on well established
theoretical work (Steel, 1967, 1968). Published data
for the length of the S-phase (TJ) in human
tumours suggests that assuming T, to be 15h is
reasonably justified for the cases in this study
(Frindel et al., 1968; Terz et al., 1971; Muggia et
al., 1974; Straus & Moran, 1977; Rabes et al.,
1979). Comparative calculations of DTpot shown in
Table II using both assumed and published T,
values supports this. Apart from these assumptions,
doubt may be cast on the calculated values of TLI.
We have discussed elsewhere the in vitro [3H]-TdR
labelling technique and why our data are probably
more accurate than many others on determination
of TLI (Kerr et al., 1983). In any case the errors
estimating DTpot in this way are not even of the
appropriate order of magnitude to account for the
large differences (often a factor of between 10 and
100) between DTpot and DT.
Actual doubling time oflung tumours
It is clear from the literature (see Table I) that,
within those groups of tumour of differing
histological type which have been adequately
studied, there is a very wide range of DT. The
values for DT in the various histological groups in
this series are similar to those published elsewhere
with one exception, our small group of
adenocarcinomata. In this group the case with the
shortest DT (23 days) was a well differentiated
adenocarcinoma of broncho-alveolar type. This
value is outwith the published range of values for
this pattern of tumour, which is from 159 to 590
days (Weiss et al., 1966; Meyer, 1973; Steele & Buell,
1973). This is a group of tumours with a wide
range of growth rates and an unusual structure
which does not fit the usual model of a solid
neoplasm. The relationship of DT to degree of
differentiation of tumours has been reviewed by
Charbit et al. (1971) who suggested that, in general,
well differentiated tumours tend to have longer DT
than poorly or undifferentiated tumours. Our
results are, in general, in keeping with this.
Although Malaise et al. (1973) produced some
evidence in their review ofpublished data that there
was a negative correlation between tumour DT and
TLI (as TLI increased, DT decreased) we cannot
support this suggestion.
The "parallel study" cases
We can find only one previous report in the
literature of the concurrent study of actual tumour
growth and cell kinetic parameters of human
tumours. Bresciani et al. (1974) studied five
squamous carcinomata of the skin, lip or gum.
They obtained detailed kinetic data including
measurements ofT. and TLI on each tumour using
an in vivo labelling technique involving intracarotid
[3H]-TdR infusion and multiple tumour biopsy.
However, their actual growth measurements were
made over only two to three weeks and involved
caliper measurements of the cutaneous nodules. In
two cases no growth was detected during the
observation period but DT was estimated based on
the maximum changes in size that could have
occurred yet which remained undetectable by their
method of tumour measurement by calipers. Cell
loss factors were found ranging from 78%-93%.
They found that the rate of cell production and the
rate of cell loss (per hour) for the tumours was
negatively correlated with DT. When they
compared cell loss factor with DT, 0 increased
slightly as DT increased.
Using pooled data on a heterogeneous series of
human tumours Steel (1972) showed that cell loss
factor 0 again increased as DT increased and
conversely that tumours generally with DT< 100
days showed a lower 0 value than those with
DT> 100 days. This group of human tumours,
however, contained both carcinomata and
sarcomata and if one considers the carcinomata
alone the change in 0 with change in DT is less
apparent. From our data comparing those tumours
with DT>80 days with those of DT<80 days there
is NO statistical difference between the groups.
In experimental animal tumours parallel studies
have been performed (Frindel et al., 1967) and a
trend of increasing cell loss factor with increasing
DT seems apparent (Steel, 1968).
A few other individual human tumours of
various site and type have cell loss values reported
in the literature (Frindel et al., 1968; Shirakawa et
al., 1970; Terz et al., 1971). These tumours had
detailed cell kinetic analysis made on them but DT
was not concurrently measured. Malaise et al.
(1973) reviewed the literature and did some
comparative calculations for a wide variety of348 K.M. KERR & D. LAMB
human tumours. Adenocarcinomata and squamous
cell carcinomata (both heterogeneous groups from
various primary sites) showed values of 71% and
91% respectively for the groups. Unfortunately
none of these data refer specifically to primary
bronchogenic adeno- or squamous cell carcinomata
so that comparison with our data is of limited
value.
Our figures do reinforce the generally held view
that cell loss from human carcinomata is high.
Furthermore our data would indicate that, in some
primary lung cancers, cell loss is very high indeed.
Almost two thirds of our primary bronchogenic
carcinomata showed cell loss of 90% or more. In
some cases 0 even exceeds the 98% figure Bone &
Camplejohn (1973) suggested rectal
adenocarcinoma might have. Although the
individual histological groups have small numbers
of cases it seems that cell loss is higher in
undifferentiated carcinomata than in the other
histological groups.
As mean cell loss increases from groups of
tumours of one histological type to another then so
does the mean TLI of the group. Thus as growth
fraction increases cell loss does also (Malaise et al.,
1973; Tubiana & Malaise, 1975). Our data confirm
the relation between cell loss increase and both
increasing % TLI and loss of tumour
differentiation. Why does this relationship exist? Is
it that cell replication carries with it a certain
"casualty rate" or that increased expansion rate in
a cell population means too great a demand on
nutrient supply leading to cell death (Malaise et al.,
1973)? Of relevance in this context is the finding
that increased cell loss makes tumour response to
chemotherapy more likely (Bagshawe, 1968); this
being especially so, as we might expect, in tumours
with a high TLI (Tubiana & Malaise, 1975). How
do these observations fit with the general clinical
experience with chemotherapy in bronchogenic
carcinoma? Chemosensitivity appears confined to a
group of small cell undifferentiated carcinomata yet
our data suggest that 0 may be just as high, or even
higher in large cell undifferentiated or squamous
cell carcinomata. In addition small cell
undifferentiated carcinomata appear to have, as a
group, shorter DT than other primary lung cancers
while mean TLI for this group is probably similar
(Kerr et al., 1983) to other groups'. Thus mean 0 in
small cell cancer as a group may be less than in
other types of bronchogenic carcinoma. Adequate
data are sparse but it is possible that more detailed
investigation may reveal subpopulations of small
cell carcinoma with "kinetic" differences.
This parallel study of actual growth and simple
cell kinetic parameters has shown that cell loss
from the tumour cell population is an important
determinant of actual growth rate in human
pulmonary neoplasms. Other important
determinants are growth fraction and cell cycle
time. In human tumours ALL these factors,
however, are difficult to measure. While we are very
aware of the errors involved with, and the
criticisms that have been levelled against the
measurements, assumptions and calculations we
have been concerned with in this study (Garland et
al., 1963; Gurland & Johnson, 1965, 1966; Steel,
1968; Steel and Lamerton, 1969) data such as these
may help towards a better understanding of the
behaviour of human bronchogenic carcinoma.
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